Flagship Harbor Advisors, LLC Neurocrine Biosciences Inc Transaction History

Flagship Harbor Advisors, LLC

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2020 Feb 08, 2021	SELL	$86.91 - $108.33 $108,289 - $134,979	-1,246 Closed	0 $0
Q3 2020 Oct 13, 2020	SELL	$96.16 - $135.15 $57,503 - $80,819	-598 Reduced 32.43%	1,246 $119,000
Q1 2020 May 12, 2020	BUY	$75.11 - $113.76 $69,777 - $105,683	929 Added 101.53%	1,844 $160,000
Q4 2019 Feb 14, 2020	BUY	$86.8 - $118.57 $14,322 - $19,564	165 Added 22.0%	915 $98,000
Q3 2019 Oct 22, 2019	BUY	$83.82 - $101.5 $62,864 - $76,125	750 New	750 $67,000
Q4 2018 Jan 28, 2019	SELL	$68.32 - $124.36 $5,192 - $9,451	-76 Closed	0 $0
Q3 2018 Nov 05, 2018	BUY	$98.88 - $125.85 $7,514 - $9,564	76 New	76 $9,000

626

94M

632K

621K

Ticker NBIX
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 95,639,296
Market Cap $13B
Description
Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, endocrine, and psychiatric disorders. The company's portfolio includes treatments for tardive dyskinesia, Parkinson's disease, endometriosis, and uterine fibroids, as well as clinical programs in various therapeutic areas. Its lead asset is INGREZZA, ...

Get notified when there are updates to the investment portfolio of Flagship Harbor Advisors, LLC, based on Form 13F filings with the SEC.

Stay updated on Flagship Harbor Advisors, LLC with notifications on news.